Synergistic anticancer effects of apatinib and nab-paclitaxel in MDA-MB-231 breast cancer cell line

doi:10.3877/cma.j.issn.2095-1221.2021.02.004

Abstract

Abstract:

Objective

To elucidate the molecular mechanisms of apatinib and nab-Paclitaxel in inducing apoptosis of MDA-MB-231 breast cancer cells.

Methods

MDA-MB-231 cells were treated with apatinib and nab-Paclitaxel alone or together and named: control group (0.1 ﹪ DMSO treatment) ; 10 μmol/L apatinib treatment group (APA group) ; 5, 10, 15, 20 nmol/L nab-Paclitaxel treatment group (Nab-p 5 groups, Nab-p 10 groups, Nab-p 15 groups and Nab-p 20 groups) and 10 μmol/L apatinib combined with 5, 10, 15, 20 nmol/L nab-Paclitaxel treatment group (APA Nab-p 5 groups, APA Nab-p 10 groups, APA Nab-p 15 groups and APA Nab-p 20 groups) . The cytotoxic activity induced by apatinib and albumin-bound paclitaxel on MDA-MB-231 cells was determined by a lactate dehydrogenase release assay. Flow cytometry was used to quantify apoptosis in different treatment groups. Effects of different intervention methods on mitochondrial membrane potential change (ΔΨ_m) of MDA-MB-231 cells were examined by JC-1 staining. Caspase-8 and Caspase-9 activities were detected by FAM-FLICA fluorescence imaging. The effects of apatinib and albumin-bound paclitaxel on DNA damage in non-tumorigenic epithelial cell line MCF-10A were evaluated by comet assay. Student's t test or one-way ANOVA was used for comparison between two groups, and Tukey post-test was used for comparison within multiple groups.

Results

Cytotoxicity test results showed that the MDA-MB-231 cell death rate in the Nab-p 20 group was close to 90 ﹪ at 24 h, and the difference was extremely significant compared with the control group (P < 0.001) . After treatment for 24 h and 48 h, about 85 ﹪ and 95 ﹪ of cell deaths were detected in the APA+Nab-p 5 group and APA+Nab-p 10 group respectively, which showed a significantly difference compared with the single-drug treatment group (Nab-p 5 group and Nab-p 10 group) (P < 0.001) . The results of flow cytometry showed that the apoptotic rate of APA+Nab-p5 (76.11±1.14) and APA+Nab-p10 (89.4±1.07) groups were significantly increased (P < 0.05) compared with the Nab-p5 (31.8±1.48) and Nab-p10 (33.25±1.77) groups. The results of mitochondrial membrane potential test showed that only depolarized cells in APA group (78.33±1.11) and Nab-p 10 group (46.74±1.75) was increased significantly at 24 h (all P < 0.01) compared with the control group (12.35±1.05) , in the single-drug treatment group, while in the combined treatment group, the depolarised cells in the APA+Nab-p 5 (68.47±1.94) and APA+Nab-p 10 group (90.03±1.79) also increased significantly (P < 0.05) . FAM-FLICA fluorescence imaging results showed that compared with the single treatment group, the caspase-8 and caspase-9 proteins in the combination group of apatinib and nab-Paclitaxel were highly activated. Comet assay analysis showed that the intervention of apatinib and nab-Paclitaxel did not significantly affect the DNA integrity of MCF-10A non-tumorigenic epithelial cell line.

Conclusion

Combined apatinib with nab-paclitaxel induces apoptosis through intrinsic mitochondrial function perturbation and extrinsic caspase activation in triple-negative breast cancer cells MDA-MB-231, and may exhibit a synergistic anticancer effect.

Key words: Apatinib, Albumin-bound paclitaxel, Synergistic effect, Breast cancer, Apoptosis

Jing Li, Zhifen Wang, Xiaohui Zhang, Gengwu Yang, Zheng Liu, Guangxu Niu. Synergistic anticancer effects of apatinib and nab-paclitaxel in MDA-MB-231 breast cancer cell line[J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2021, 11(02): 90-98.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhxbygxbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-1221.2021.02.004

https://zhxbygxbzz.cma-cmc.com.cn/EN/Y2021/V11/I02/90

Figures/Tables 8

References 24

1	Schiff PB, Horwitz SB. Taxol stabilizes microtubules in mouse fibroblast cells[J]. Proc Natl Acad Sci U S A, 1980, 77(3):1561-1565.
2	于海涛. 抗癌药物-紫杉醇合成和应用研究进展[J]. 黑龙江科技信息, 2017(5):129-129.
3	Verweij J, Clavel M, Chevalier B. Paclitaxel (taxoltm) and docetaxel (taxoteretm): Not simply two of a kind[J]. Ann Oncol, 1994, 5(6):495-505.
4	潘力敏. 白蛋白结合型紫杉醇与多西他赛在HER-2阴性早期乳腺癌新辅助治疗中的临床对比[D]. 郑州:郑州大学, 2019.
5	Desai N, Trieu V, Yao Z, et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, abi-007, compared with cremophor-based paclitaxel[J]. Clin Cancer Res, 2006, 12(4):1317-24.
6	Desai NP, Trieu V, Hwang LY et al. Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of her2 and sparc status[J]. Anticancer Drugs, 2008, 19(9):899-909.
7	Gradishar WJ, Tjulandin S, Davidson N, et al. Phase iii trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer[J]. J Clin Oncol, 2005, 23(31):7794-7803.
8	杨芳. 阿帕替尼在晚期转移性三阴性乳腺癌中的临床疗效及预后分析[D].开封:河南大学, 2019.
9	王明婷. 贝伐珠单抗联合阿帕替尼对肺癌抗肿瘤作用实验研究[D]. 泸州:西南医科大学, 2020.
10	董世奇，张爱杰，樊慧蓉. 阿帕替尼临床应用的研究进展[J]. 药物评价研究, 2020, 43(07):1446-1451.
11	Zhang H. Apatinib for molecular targeted therapy in tumor[J]. Drug Des Devel Ther, 2015, 9:6075-6081.
12	张香梅，何明，陈新, 等. 阿帕替尼在进展期恶性肿瘤治疗中的研究进展[J]. 广东医学, 2017, 38(S2):168-170+173.
13	李蓉. 阿帕替尼联合白蛋白紫杉醇在耐药性卵巢癌中的作用[D]. 太原:山西医科大学, 2020.
14	Kundranda MN, Niu J. Albumin-bound paclitaxel in solid tumors: Clinical development and future directions[J]. Drug Des Devel Ther, 2015, 9:3767-3777.
15	Zong Y, Wu J, Shen K. Nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy of breast cancer: A systematic review and meta-analysis[J]. Oncotarget, 2017, 8(10):17360-17372.
16	Park CH, Han SE, Nam-Goong IS, et al. Combined effects of baicalein and docetaxel on apoptosis in 8505c anaplastic thyroid cancer cells via downregulation of the erk and akt/mtor pathways[J]. Endocrinol Metab (Seoul), 2018, 33(1):121-132.
17	Speyer CL, Bukhsh MA, Jafry WS, et al. Riluzole synergizes with paclitaxel to inhibit cell growth and induce apoptosis in triple-negative breast cancer[J]. Breast Cancer Res Treat, 2017, 166(2):407-419.
18	Ireland L, Santos A, Campbell F, et al. Blockade of insulin-like growth factors increases efficacy of paclitaxel in metastatic breast cancer[J]. Oncogene, 2018, 37(15):2022-2036.
19	Johnson LV, Walsh ML, Bockus BJ, et al. Monitoring of relative mitochondrial membrane potential in living cells by fluorescence microscopy[J]. J Cell Biol, 1981, 88(3):526-535.
20	Elmore S. Apoptosis: A review of programmed cell death[J]. Toxicol Pathol, 2007, 35(4):495-516.
21	Debatin KM, Poncet D, Kroemer G. Chemotherapy: Targeting the mitochondrial cell death pathway[J]. Oncogene, 2002, 21(57):8786-8803.
22	Heiskanen KM, Bhat MB, Wang HW, et al. Mitochondrial depolarization accompanies cytochrome c release during apoptosis in pc6 cells[J]. J Biol Chem, 1999, 274(9):5654-5658.
23	Salvesen GS, Dixit VM. Caspases: Intracellular signaling by proteolysis[J]. Cell, 1997, 91(4):443-446.
24	Rossi D, Gaidano G. Messengers of cell death: Apoptotic signaling in health and disease[J]. Haematologica, 2003, 88(2):212-218.

分组	实验次数	6 h	12 h	24 h	48 h
阴性对照	3	2.31±1.83	2.16±0.99	3.74±1.67	3.97±2.31
APA	3	2.24±0.86^a	27.43±1.52^a	55.72±2.13^a	86.05±2.61^a
Nab-p 5	3	2.45±1.58	1.73±1.84	5.41±1.37	17.82±1.95^a
Nab-p 10	3	1.55±2.11	1.68±2.30	32.03±1.55^a	31.94±1.84^a
Nab-p 15	3	5.11±0.79^a	20.02±1.22^a	64.37±2.34^a	90.13±1.05^a
Nab-p 20	3	36.31±1.92^a	54.68±1.73^a	83.72±1.67^a	93.56±1.82^a
APA+Nab-p 5	3	5.23±2.44	33.51±1.40^ab	82.26±1.27^ab	95.15±1.88^ab
APA+Nab-p 10	3	5.16±0.74^ab	26.72±1.09^ab	83.26±2.01^ab	96.02±1.44^ab
APA+Nab-p 15	3	21.23±0.81^ab	73.04±1.35^ab	89.66±1.79^ab	96.85±1.99^ab
APA+Nab-p 20	3	42.45±1.93^a	97.26±1.58^ab	91.03±2.25^a	97.91±0.76
F值		432.074	510.147	257.155	369.602
P值		< 0.001	< 0.001	< 0.001	< 0.001

分组	实验次数	6 h	12 h	24 h	48 h
阴性对照	3	2.31±1.83	2.16±0.99	3.74±1.67	3.97±2.31
APA	3	2.24±0.86^a	27.43±1.52^a	55.72±2.13^a	86.05±2.61^a
Nab-p 5	3	2.45±1.58	1.73±1.84	5.41±1.37	17.82±1.95^a
Nab-p 10	3	1.55±2.11	1.68±2.30	32.03±1.55^a	31.94±1.84^a
Nab-p 15	3	5.11±0.79^a	20.02±1.22^a	64.37±2.34^a	90.13±1.05^a
Nab-p 20	3	36.31±1.92^a	54.68±1.73^a	83.72±1.67^a	93.56±1.82^a
APA+Nab-p 5	3	5.23±2.44	33.51±1.40^ab	82.26±1.27^ab	95.15±1.88^ab
APA+Nab-p 10	3	5.16±0.74^ab	26.72±1.09^ab	83.26±2.01^ab	96.02±1.44^ab
APA+Nab-p 15	3	21.23±0.81^ab	73.04±1.35^ab	89.66±1.79^ab	96.85±1.99^ab
APA+Nab-p 20	3	42.45±1.93^a	97.26±1.58^ab	91.03±2.25^a	97.91±0.76
F值		432.074	510.147	257.155	369.602
P值		< 0.001	< 0.001	< 0.001	< 0.001

分组	实验次数	晚期凋亡率		早期凋亡率		总凋亡率
分组	实验次数	24 h	48 h	24 h	48 h	24 h	48 h
阴性对照	3	11.34±0.55	18.50±1.72	10.17±1.34	13.16±1.38	21.51±1.50	31.66±1.26
APA	3	30.42±0.99^a	50.35±1.93^a	6.73±1.69^a	19.24±1.82^a	45.24±1.36^a	69.59±1.85^a
Nab-p 5	3	25.07±2.02^a	18.74±2.01	1.73±1.84^a	22.51±1.35^a	31.8±1.48^a	41.25±2.11^a
APA+Nab-p 5	3	63.45±0.94^a	87.05±1.70^a	12.66±1.25	2.18±1.04^a	76.11±1.14^ab	89.23±1.66^ab
Nab-p 10	3	23.51±0.79^a	30.63±2.14^a	9.74±2.03	15.25±1.85	33.25±1.77^a	45.88±1.50^a
APA+Nab-p 10	3	86.25±1.84^ab	90.37±1.95^ab	3.25±0.91^ab	2.93±0.74^ab	89.4±1.07^ab	93.3±1.10^ab
F值		609.227	783.285	526.841	539.104	733.972	527.734
P值		< 0.001	< 0.001	< 0.001	< 0.001	< 0.001	< 0.001

分组	实验次数	晚期凋亡率		早期凋亡率		总凋亡率
分组	实验次数	24 h	48 h	24 h	48 h	24 h	48 h
阴性对照	3	11.34±0.55	18.50±1.72	10.17±1.34	13.16±1.38	21.51±1.50	31.66±1.26
APA	3	30.42±0.99^a	50.35±1.93^a	6.73±1.69^a	19.24±1.82^a	45.24±1.36^a	69.59±1.85^a
Nab-p 5	3	25.07±2.02^a	18.74±2.01	1.73±1.84^a	22.51±1.35^a	31.8±1.48^a	41.25±2.11^a
APA+Nab-p 5	3	63.45±0.94^a	87.05±1.70^a	12.66±1.25	2.18±1.04^a	76.11±1.14^ab	89.23±1.66^ab
Nab-p 10	3	23.51±0.79^a	30.63±2.14^a	9.74±2.03	15.25±1.85	33.25±1.77^a	45.88±1.50^a
APA+Nab-p 10	3	86.25±1.84^ab	90.37±1.95^ab	3.25±0.91^ab	2.93±0.74^ab	89.4±1.07^ab	93.3±1.10^ab
F值		609.227	783.285	526.841	539.104	733.972	527.734
P值		< 0.001	< 0.001	< 0.001	< 0.001	< 0.001	< 0.001

分组	实验次数	极化细胞		去极化细胞
分组	实验次数	24 h	48 h	24 h	48 h
阴性对照	3	79.02±2.13	59.63±1.69	12.35±1.05	22.48±1.35
APA	3	13.46±1.50^a	2.38±0.59^a	78.33±1.11^a	85.36±1.84^a
Nab-p 5	3	75.81±1.62	48.35±2.05	17.24±1.70	38.14±1.92
APA+Nab-p 5	3	20.63±1.17^ab	3.14±1.73^ab	68.47±1.94^ab	86.03±1.71^ab
Nab-p 10	3	52.05±2.03^a	6.37±1.99^a	46.74±1.75^a	68.44±1.50^a
APA+Nab-p 10	3	6.94±1.88^ab	2.52±1.34^ab	90.03±1.79^ab	94.27±1.44^ab
F值		520.471	974.113	801.356	736.066
P值		< 0.001	< 0.001	< 0.001	< 0.001

Please choose a citation manager

Content to export